Compared to more rare mutations in the RAS family, activating mutations of the PI3K-Akt axis appear in approximately 20% of bladder carcinomas, conferring resistance to FGFR inhibitors. The gene discussed is PIK3CB; the disease is urinary bladder carcinoma.